EU New Drug Approvals 2018: Anticancers, Orphans, The First CAR-Ts – And More
Executive Summary
New drug approvals in the EU were again dominated by oncology in 2018, although medicines for infectious diseases came a close second. The number of orphan drugs more than doubled over the previous year, to 17. There were also some key new arrivals in the areas of multiple sclerosis, genetic disorders, metabolism and migraine.